Interplay Between Insulin Resistance and Estrogen Deficiency as co- Activators in Carcinogenesis

Zsuzsanna Suba
  • Pathology & Oncology Research, October 2011, Springer Science + Business Media
  • DOI: 10.1007/s12253-011-9466-8

Insulin resistance and defective estrogen effect are collaborating in cancer risk

What is it about?

Deepening insulin resistance leads to the defect of estrogen synthesis and signaling, while low estrogen level or estrogen receptor defect inhibits cellular glucose uptake leading to insulin resistance.

Why is it important?

Patients with insulin resistance and/or with estrogen signaling defect may be treated by insulin sensitizers and/or exogenous estrogen (oral contraceptive, postmenopausal hormone replacement) for the prevention of cancer development. Moreover, higher estrogen doses are effective even against advanced cancers.

Perspectives

professor Zsuzsanna Suba
National Institute of Oncology Budapest

We are on the route to regard estrogens as beneficial treatments against metabolic syndrome and type-2 diabetes.

Read Publication

http://dx.doi.org/10.1007/s12253-011-9466-8

The following have contributed to this page: professor Zsuzsanna Suba